In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chloe Kent

Senior Reporter

London, UK

Chloe is an award-winning journalist who has specialized in health reporting throughout her career, with a particular focus on women's health and access to medicine. Before joining Generics Bulletin she worked for B2B publishing consortium Verdict, writing about medical technology and pharmaceuticals. Having graduated from the University of York, she went on to train as a journalist with the Press Association.

Latest From Chloe Kent

Off-Patent Personnel Moves In 2023 Reflect Growing Interest In Innovator Space

Executive changes at both Viatris and Teva in 2023 saw the companies shift their focus towards the innovator industry. Plus, trade groups saw some significant personnel shakeups, Alvotech expressed hope that new hires would help to resolve manufacturing approval issues, Biocon made changes to its management structure, and more.

Executive Changes Leadership

A Year Of Change: Viatris Ploughs Ahead With Brand Ambitions

In 2024, Viatris will initiate the second phase of its long-term business plan, which will see it step away from the perceived volatility of the generics space and begin to move toward innovative and high-growth products. The past year has seen it lay the groundwork for this pivot, shedding surplus business units and making significant hires from the branded space.

Companies Strategy

Treat, Prevent, Restore: Sensorion’s Approach To Hearing Loss

Hearing loss lacks pharmacological treatment options, with patients instead relying on medical devices or going untreated. In Vivo spoke to French biotech Sensorion, which is targeting a number of hearing loss indications with small-molecule drugs and gene therapies.

Innovation Clinical Trials

Elite Ships US Generic Adderall Amid Ongoing Shortages

As the nationwide shortage of Adderall continues in the US, Elite Pharmaceuticals has announced the first shipment of its generic version to partner Prasco.

Supply Chain Generic Drugs

Mironid On Reducing The Burden Of Polycystic Kidney Disease

Scottish biotech Mironid is in the preclinical stages of developing a treatment for autosomal dominant polycystic kidney disease, a genetic condition which for around half of patients can led to kidney failure by the time they reach 60 years of age. In Vivo spoke to chief medical officer Cass Kelleher about the company’s development strategy.

Leadership Innovation

Towa Buys Out Kamata Following Facility Expansion And Guidance Raise

Japanese generics firm Towa has acquired Kamata as a wholly owned subsidiary, in order to increase soft capsule manufacturing capacity for its Sunsho segment. The firm has also announced that it has completed expansion works at its Yamagata plant and made a moderate revision to its financial forecast.

Generic Drugs Strategy
See All